<DOC>
	<DOCNO>NCT01324128</DOCNO>
	<brief_summary>This Phase 3 , randomise , active control , multicentre study investigate safety efficacy PA21 , phosphate binder , control hyperphosphataemia dialysis patient . The primary objective establish efficacy PA21 lower phosphate level patient .</brief_summary>
	<brief_title>A Phase 3 Study Investigate Safety Efficacy PA21 , Phosphate Binder , Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Dialysis patient hyperphosphataemia ( ≥ 1.94 mmol/L ; ≥ 6.0 mg/dL ) Stable dose phosphate binder Written inform consent Hyper/hypo calcemia ; hyper intact parathyroid hormone ( iPTH ) Other significant medical condition Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>PA21</keyword>
	<keyword>Phosphate Binder</keyword>
</DOC>